Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg

Glaukos Corporation30 enrolled

Overview

Clinical in-use observational trial to evaluate the updated inserter for the Travoprost Intracameral implant using the updated inserter (Model G2-TRIO)

The objective of this study is to evaluate the administration of the Travoprost intracameral implant using the updated inserter (Model G2-TRIO)

Study Type

OBSERVATIONAL

Enrollment

Conditions

Open-angle Glaucoma, Ocular Hypertension

Interventions

TravoprostCOMBINATION_PRODUCT

Travoprost intracameral implant, 75mcg administered using the sterile, single-dose updated inserter (Model G2-TRIO)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of Open-angle glaucoma * 18 years of age or older Exclusion Criteria: * Subject who is breast-feeding or pregnant

Locations (1)

Glaukos Investigative Site

Kenosha, Wisconsin, United States

RECRUITING

Outcomes

Primary Outcomes

Successful implantation

Investigator's ability to follow the Instructions For Use/Prescribing Information and correctly administer the model G2-TRIO travoprost intracameral implant 75mcg with the updated inserter

Time frame: 1 day

Central Contacts

Study Director

CONTACT

949-739-8749 idoseclinical@glaukos.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.